Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


ASN: Bardoxolone Methyl No Benefit in T2DM, Stage 4 CKD
Trial stopped early due to increased rate of cardiovascular events with bardoxolone methyl
This article is older than one year and is no longer available.

Copyright © 2013 HealthDay. All rights reserved.

September 1, 2015

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Nonalbuminuric CKD Ups Cardiovascular Morbidity in T1DM

AMA: Ruling Makes It Easier for Insurers to Terminate Doctors

Modest Predictive Accuracy for CHA2DS2-VASc in Heart Failure

Intravenous Cyclosporine Doesn't Improve STEMI Outcomes

FDA Warns of Joint Pain Tied to DPP-4 Inhibitors

Osteonecrosis of Jaw Risk Highest for IV Bisphosphonate Use